Zhejiang province collects DAA drug information and prepares for suspected purchase

Yesterday, Zhejiang Pharmaceutical equipment procurement platform released the notice on collecting information about direct anti viral (DAA) drugs for hepatitis C, which will carry out information collection on products and prices of DAA drugs for hepatitis C Hepatitis C (HCV); the global rate of HCV infection is about 3%, estimated to be about 180 million people infected with HCV, with about 35000 new cases of hepatitis C each year At present, interferon antiviral therapy is widely used in the world, the prognosis can reach 90%, but because of its serious side effects, especially myelosuppression, and hepatitis C also has a very strong secretive, most patients found that the symptoms are late, the cure rate is greatly reduced DAA: a new type of oral direct antiviral drug in recent years For the treatment of chronic hepatitis C can be described as a major discovery, priority to increase the cure rate of hepatitis C, for late hepatitis C patients brought hope Appendix: information table of direct anti viral (DAA) drugs for hepatitis C doc this article is the content reprinted by yaozhi.com, the copyright belongs to the original author, and the purpose of reprinting is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.